Hero banner

Empagliflozin in the Treatment of Chronic Heart Failure

Heart Failure (HF) affects almost 60 million people worldwide (1) – Let’s take action now!

This is an informative and resourceful hub that will help to support your clinical practice, and your knowledge of the role of SGLT2 Inhibitor Empagliflozin in the treatment of chronic heart failure, by:

  • Providing a library of materials, many of which you can download
  • Giving access to the latest guideline update from ESC 20232
  • Detailing the EMPEROR-Preserved trial outcomes3
  • Offering evidence-based information of the benefits of Empagliflozin in HF4

This resource hub is supported by the Boehringer Ingelheim and Lilly Alliance.

1. Groenewegen A, Rutten FH, Mosterd A, W. Hoes A, Epidemiology of heart failure. European Journal of Heart Failure 2020; 22, 1342-1356. doi: 10.1002/ejhf.1858

2. McDonagh TA, Metra M, Adamo M, et al. 2023 Focused Update of the 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure [published online ahead of print, 2023 Aug 25]. Eur Heart J. 2023;ehad195. doi:10.1093/eurheartj/ehad195 

3. Anker SD, Butler J, Filippatos G, et al; EMPEROR-Preserved Trial Investigators. Empagliflozin in heart failure with a preserved ejection fraction. N Engl J Med. 2021;385(16):1451-1461. doi:10.1056/NEJMoa2107038 (EMPEROR- Preserved results and the publication's Supplementary Appendix.) 

4.JARDIANCE® [summary of product characteristics]. Ingelheim am Rhein, Germany: Boehringer Ingelheim International GmbH; [December 2023].

Latest Content

What's New for Chronic Heart Failure?

The 2023 ESC Congress introduced a focused update of the 2021 heart failure guidelines, with new recommendations. SGLT2 inhibitors, such as JARDIANCE®, have now received a class I level A recommendation for the treatment of chronic heart failure across the LVEF spectrum; HFrEF, HFmrEF, and HFpEF.1


Listen to Prof Theresa McDonagh, the co-chair of both the 2021 ESC HF guidelines2 and the 2023 ESC Focused Update1, explaining the evidence behind this new recommendation.

 

1. McDonagh TA, Metra M, Adamo M, et al. 2023 Focused Update of the 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure [published online ahead of print, 2023 Aug 25]. Eur Heart J. 2023;ehad195. doi:10.1093/eurheartj/ehad195 

2. McDonagh TA, Metra M, Adamo M, et al; ESC Scientific Document Group. 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure. Eur J Heart Fail. 2021;00:1-128. doi:10.1093/eurheartj/ehab368

 

Benefits of Jardiance in HF Treatment

JARDIANCE®: Proven Benefits Across the LVEF Spectrum

Proven protection

Reduced risk of CV death and HHF across the LVEF spectrum 1,2

Protected the kidneys by slowing the decline of renal function †1,2

Additionally, provided early and sustained symptom relief 4,5


Proven safety and tolerability profile across multiple trials3

 

Simple dosing: oral, once daily, no titration ‡3

†The rate of decline in eGFR was a prespecified secondary outcome of the EMPEROR-Reduced and EMPEROR-Preserved trials.

‡When JARDIANCE is used in combination with a sulphonylurea or with insulin, a lower dose of the sulphonylurea or insulin may be considered to reduce the risk of hypoglycaemia. 

 

Download references:

Download

Safety

Safety Information

Proven Safety and Tolerability Profile Across Multiple Trials1

Very common AEs:
  • Volume depletion: The frequency was increased in patients aged 75 years and older (JARDIANCE 10mg 2.3% vs placebo 2.1%) compared to overall (JARDIANCE® 10 mg 0.6% vs placebo 0.3%) The most frequent adverse reaction of the pooled EMPEROR-Reduced and EMPEROR-Preserved studies was volume depletion (JARDIANCE® 10 mg 11.4% vs placebo 9.7%).
  • Hypoglycaemia (when used with a sulphonylurea or insulin): A lower dose of the sulphonylurea or insulin may be considered to reduce the risk.
Common AEs:
  • Urinary tract infections, serum lipids increased (total cholesterol), genital infections, increased urination, thirst, constipation, pruritus (generalised), and rash.
Uncommon AEs:
  • Angioedema, blood creatinine increased/glomerular filtration rate decreased, diabetic ketoacidosis, dysuria, haematocrit increased, and urticaria.
Rare AEs:
  • Necrotising fasciitis of the perineum (Fournier’s gangrene).

Download the Jardiance SmPC via the download button below.

Reporting Adverse Events Side Effects 

1.JARDIANCE [summary of product characteristics]. Ingelheim am Rhein, Germany; Boehringer Ingelheim International GmbH

Download